



Please type a plus sign (+) inside this box → ☐

**RECEIVED**  
 AUG 09 2001  
 TECH CENTER 1600/2900

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/600,826	
			Filing Date	September 7, 2000	
			First Named Inventor	Axel ULLRICH	
			Group Art Unit	1614	
			Examiner Name	Unassigned	
			Attorney Docket Number	205884	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication
		Application or Patent Number	Kind Code		

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS					Translation	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			Yes	No* +
<i>J</i>	AG	BUCHDUNGER et al., "4,5-bis (4-flouroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent <i>in vivo</i> antitumor activity," <i>Clin. Cancer Res.</i> , 1 (8), 813-821 (1995)				
<i>J</i>	AH	CIARDELLO et al., "Cooperative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells," <i>Clin. Cancer Res.</i> , 1 (2), 161-167 (1995)				
<i>J</i>	AI	COLL-FRESNO et al., "Cytotoxic activity of a diptheria toxin/FGF6 mitotoxin on human tumour cell lines," <i>Oncogene</i> , 14 (2), 243-247 (1997)				
<i>J</i>	AJ	DINNEY et al., "Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide," <i>Clin. Cancer Res.</i> , 3 (2), 161-168 (1997)				
<i>J</i>	AK	HAN et al., "Preferential inhibition of glioblastoma cell with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate," <i>Oncol. Res.</i> , 9 (11-12), 581-587 (1997)				
<i>J</i>	AL	NORMANNO et al., "Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides," <i>Clin. Cancer Res.</i> , 2 (3), 601-609 (1996)				
<i>J</i>	AM	PARTANEN et al., "FGFR-4, a novel acidic growth factor receptor with a distinct expression pattern," <i>EMBO J.</i> , 10 (6), 1347-1354 (1991)				
<i>J</i>	AN	RUBIN GRANDIS et al., "Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells," <i>Oncogene</i> , 15 (4), 409-416 (1997)				
<i>J</i>	AO	SHOWALTER et al., "Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases," <i>Pharmacol. Ther.</i> , 76 (1-3), 55-61 (1997)				
<i>J</i>	AP	UEHARA, "Recent advances in development of antitumor tyrosine kinase inhibitors," <i>Gan To Kagaku</i> , 24 (11), 1536-1540 (1997)			Abstract	

Examiner Signature		Date Considered	3-5-03
--------------------	--	-----------------	--------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).  
 + An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

GROUP  
1614

[illegible]

AF CALBIOCHEM® Signal Transduction Catalog & Technical Resource, p. 259 (1998)

DATE CONSIDERED \_\_\_\_\_

\*A concise statement of relevance is being submitted in lieu of a translation. 37 CFR § 1.98(b).